CEFTIBUTEN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H14N4O6S2
Molecular Weight	410.425
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC=C(N1C(=O)[C@H]2NC(=O)C(=C/CC(O)=O)\C3=CSC(N)=N3)C(O)=O

InChI

InChIKey=UNJFKXSSGBWRBZ-BJCIPQKHSA-N

InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/ceftibuten.html http://www.rxlist.com/cedax-drug.htm http://www.wikidoc.org/index.php/Ceftibuten

Ceftibuten is a 3rd generation cephalosporin that is FDA approved for the treatment of acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis. Ceftibuten exerts its bactericidal action by binding to essential target proteins of the bacterial cell wall. This binding leads to inhibition of cell-wall synthesis. Common adverse reactions include diarrhea, nausea, vomiting and headache. The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers. Each volunteer was administered one 400-mg ceftibuten capsule. A single dose of liquid antacid did not affect the Cmax or AUC of ceftibuten; however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten Cmax by 23% and ceftibuten AUC by 16%.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peptidoglycan synthase FtsI 5 Target ID: P0AD68 Gene ID: 944799.0 Gene Symbol: ftsI Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2120175	Inhibitor 8297
Penicillin-binding protein 1A 45 Target ID: P02918 Gene ID: 947907.0 Gene Symbol: mrcA Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2120175	Inhibitor 8297
Penicillin-binding protein 1B 22 Target ID: P02919 Gene ID: 944843.0 Gene Symbol: mrcB Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2120175	Inhibitor 8297
Penicillin-binding protein 2 24 Target ID: P0AD65 Gene ID: 945240.0 Gene Symbol: mrdA Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2120175	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Acute bacterial exacerbation of chronic bronchitis 31 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	Curative	Approved 8429	CEDAX Approved Use Ceftibuten is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the Ceftibuten product for the prophylaxis of subsequent rheumatic fever are not available. Launch Date 8.1941758E11
Acute bacterial otitis media 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	Curative	Approved 8429	CEDAX Approved Use Ceftibuten is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the Ceftibuten product for the prophylaxis of subsequent rheumatic fever are not available. Launch Date 8.1941758E11
Pharyngitis 31 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	Curative	Approved 8429	CEDAX Approved Use Ceftibuten is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the Ceftibuten product for the prophylaxis of subsequent rheumatic fever are not available. Launch Date 8.1941758E11
Tonsillitis 36 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	Curative	Approved 8429	CEDAX Approved Use Ceftibuten is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the Ceftibuten product for the prophylaxis of subsequent rheumatic fever are not available. Launch Date 8.1941758E11

C_max

Value	Dose	Analyte	Population
14.98 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.85 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
18.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
23.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.85 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	9 mg/kg bw single, oral dose: 9 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Analyte	Population
73.74 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
80.22 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
82.53 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
73.7 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
118 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
42.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
79.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
56 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	9 mg/kg bw single, oral dose: 9 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Analyte	Population
2.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.37 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726497/	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.01 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7726498/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	9 mg/kg bw single, oral dose: 9 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	CEFTIBUTEN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
35% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		CEFTIBUTEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
35% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050685s011,050686s014lbl.pdf	9 mg/kg bw single, oral dose: 9 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:		CEFTIBUTEN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7830237/	healthy, 18 - 26 years n = 12 Health Status: healthy Age Group: 18 - 26 years Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/7830237/	Sources: https://pubmed.ncbi.nlm.nih.gov/7830237/
800 mg single, oral Highest studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7726498/	healthy, 19 - 38 years n = 18 Health Status: healthy Age Group: 19 - 38 years Sex: M Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/7726498/	Sources: https://pubmed.ncbi.nlm.nih.gov/7726498/
9 mg/kg 1 times / day steady, oral Recommended Dose: 9 mg/kg, 1 times / day Route: oral Route: steady Dose: 9 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7567313/	unhealthy, mean 4.9 years n = 1152 Health Status: unhealthy Condition: Infectious Disease Age Group: mean 4.9 years Sex: M+F Population Size: 1152 Sources: https://pubmed.ncbi.nlm.nih.gov/7567313/	Disc. AE: Gastrointestinal disorders... Other AEs: Gastrointestinal disorders... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (0.9%) Other AEs: Gastrointestinal disorders (160 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/7567313/

AEs

AE	Significance	Dose	Population
Gastrointestinal disorders	0.9% Disc. AE	9 mg/kg 1 times / day steady, oral Recommended Dose: 9 mg/kg, 1 times / day Route: oral Route: steady Dose: 9 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7567313/	unhealthy, mean 4.9 years n = 1152 Health Status: unhealthy Condition: Infectious Disease Age Group: mean 4.9 years Sex: M+F Population Size: 1152 Sources: https://pubmed.ncbi.nlm.nih.gov/7567313/
Gastrointestinal disorders	160 patients	9 mg/kg 1 times / day steady, oral Recommended Dose: 9 mg/kg, 1 times / day Route: oral Route: steady Dose: 9 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7567313/	unhealthy, mean 4.9 years n = 1152 Health Status: unhealthy Condition: Infectious Disease Age Group: mean 4.9 years Sex: M+F Population Size: 1152 Sources: https://pubmed.ncbi.nlm.nih.gov/7567313/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	PEPT1 49 PEPT2 32

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
PEPT1 49	substrate 3367 Sources: https://jpet.aspetjournals.org/content/307/2/626.short Page: -	yes
PEPT2 32	substrate 3367 Sources: https://www.sciencedirect.com/science/article/pii/S0005273696002349 Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3510	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3510
ChemicalBook	CB7299436	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7299436
MolPort	MolPort-003-666-607	https://www.molport.com/shop/molecule-link/MolPort-003-666-607
ZINC	ZINC000003871967	http://zinc15.docking.org/substances/ZINC000003871967

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Ceftibuten must be administered at least 2 hours before or 1 hour after a meal. maximum daily dose is 400 mg (during 10 days).

Route of Administration: Oral

In Vitro Use Guide

Ceftibuten displayed high activity against Haemophilus influenzae and Branhamella catarrhalis. There was reduced activity against Streptococcus pneumoniae (MIC90 16 mg/l).

Name

Type

Language

CEFTIBUTEN

Official Name

English

PF-07612577 component PF-06264006

Code

English

ceftibuten [INN]

Common Name

English

(+)-(6R,7R)-7-((Z)-2-(2-AMINO-4-THIAZOLYL)-4-CARBOXYCROTONAMIDO)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

CEFTIBUTEN [USAN]

Common Name

English

SCH-39720

Code

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((2-(2-AMINO-4-THIAZOLYL)-4-CARBOXY-1-OXO-2-BUTENYL)AMINO)-8-OXO-, (6R-(6.ALPHA.,7.BETA.(Z)))-

Common Name

English

CEFTIBUTIN [VANDF]

Common Name

English

CEFTIBUTEN [MI]

Common Name

English

CEFTIBUTEN [VANDF]

Common Name

English

ACHN383

Code

English

7432-S

Code

English

PF-06264006

Code

English

ACHN-383

Code

English

Ceftibuten [WHO-DD]

Common Name

English

SCH 39720

Code

English

NSC-758925

Code

English

Classification Tree Code System Code

NDF-RT

N0000011161